European Heart Journal (Eur Heart J)

Publisher: European Society of Cardiology, Oxford University Press (OUP)

Journal description

European Heart Journal is an international, English language, peer-reviewed journal of cardiology. European Heart Journal is an official professional journal of the European Society of Cardiology and is published twice monthly by W.B. Saunders, a Harcourt Health Sciences Company. European Heart Journal aims to publish the highest quality material, both clinical and scientific, on all aspects of cardiology. European Heart Journal includes research findings, technical evaluations, review articles, and in addition provides a forum for the exchange of information and views on all professional cardiology issues including education. European Heart Journal promotes excellence in the profession of cardiology by its commitment to the publication of research, by its support for education, and by its encouragement and dissemination of best practice. The European Heart Journal is cited in : Science Citiation Index, SCISearch, Research Alert, Medical Documentation Sevice, Current Contents/Clinical Medicine, Chemical Abstracts, EMBASE and Index Medicus. Harcourt Home

Current impact factor: 14.72

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2013 / 2014 Impact Factor 14.723
2012 Impact Factor 14.097
2011 Impact Factor 10.478
2010 Impact Factor 10.046
2009 Impact Factor 9.8
2008 Impact Factor 8.917

Impact factor over time

Impact factor

Additional details

5-year impact 11.99
Cited half-life 5.30
Immediacy index 3.45
Eigenfactor 0.11
Article influence 4.36
Website European Heart Journal website
Other titles European heart journal (Online), European heart journal
ISSN 1522-9645
OCLC 40309576
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Oxford University Press (OUP)

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months embargo
  • Conditions
    • Pre-print can only be posted prior to acceptance
    • Pre-print must be accompanied by set statement (see link)
    • Pre-print must not be replaced with post-print, instead a link to published version with amended set statement should be made
    • Pre-print on author's personal website, employer website, free public server or pre-prints in subject area
    • Post-print in Institutional repositories or Central repositories
    • Publisher's version/PDF cannot be used
    • Published source must be acknowledged
    • Must link to publisher version
    • Set phrase to accompany archived copy (see policy)
    • Eligible authors may deposit in OpenDepot
    • The publisher will deposit in PubMed Central on behalf of NIH authors
    • Publisher last contacted on 19/02/2015
    • This policy is an exception to the default policies of 'Oxford University Press (OUP)'
  • Classification
    ​ yellow

Publications in this journal

  • European Heart Journal 03/2015; 36(12):702-707. DOI:10.1093/eurheartj/ehv025
  • European Heart Journal 03/2015; 36(12):699-701. DOI:10.1093/eurheartj/ehv040
  • European Heart Journal 03/2015; DOI:10.1093/eurheartj/ehv082
  • [Show abstract] [Hide abstract]
    ABSTRACT: Magnetic resonance imaging (MRI) has long been regarded a general contraindication in patients with cardiovascular implanted electronic devices such as cardiac pacemakers or cardioverter defibrillators (ICDs) due to the risk of severe complications and even deaths caused by interactions of the magnetic resonance (MR) surrounding and the electric devices. Over the last decade, a better understanding of the underlying mechanisms responsible for such potentially life-threatening complications as well as technical advances have allowed an increasing number of pacemaker and ICD patients to safely undergo MRI. This review lists the key findings from basic research and clinical trials over the last 20 years, and discusses the impact on current day clinical practice. With 'MR-conditional' devices being the new standard of care, MRI in pacemaker and ICD patients has been adopted to clinical routine today. However, specific precautions and specifications of these devices should be carefully followed if possible, to avoid patient risks which might appear with new MR technology and further increasing indications and patient numbers. © The Author 2015. Published by Oxford University Press on behalf of the European Society of Cardiology.
    European Heart Journal 03/2015; DOI:10.1093/eurheartj/ehv086
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aims: Osteopontin (OPN) is a multifunctional cytokine critically involved in cardiac fibrosis. However, the underlying mechanisms are unresolved. Noncoding RNAs are powerful regulators of gene expression and thus might mediate this process. Methods and Results: OPN and miR-21 were significantly increased in cardiac biopsies of patients with myocardial fibrosis. Ang II infusion via osmotic minipumps led to specific miRNA regulations with miR-21 being strongly induced in wildtype (WT) but not OPN knockout (KO) mice. This was associated with enhanced cardiac collagen content, myofibroblast activation, ERK-MAP kinase as well as AKT signalling pathway activation and a reduced expression of Phosphatase and Tensin Homologue (PTEN) as well as SMAD7 in WT but not OPN KO mice. In contrast, cardiotropic AAV9-mediated overexpression of OPN in vivo further enhanced cardiac fibrosis. In vitro, Ang II induced expression of miR-21 in WT cardiac fibroblasts, while miR-21 levels were unchanged in OPN KO fibroblasts. As pri-miR-21 was also increased by Ang II, we studied potential involved upstream regulators; Electrophoretic Mobility Shift and Chromatin Immunoprecipitation analyses confirmed activation of the miR-21 upstream-transcription factor AP-1 by Ang II. Recombinant OPN directly activated miR-21, enhanced fibrosis and activated the phosphoinositide 3-kinase pathway. Locked nucleic acid-mediated miR-21 silencing ameliorated cardiac fibrosis development in vivo. Conclusion: In cardiac fibrosis related to Ang II, miR-21 is transcriptionally activated and targets PTEN/SMAD7 resulting in increased fibroblast survival. OPN KO animals are protected from miR-21 increase and fibrosis development due to impaired AP-1 activation and fibroblast activation.
    European Heart Journal 03/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aims To prospectively validate the SYNTAX Score II and forecast the outcomes of the randomized Evaluation of the Xience Everolimus-Eluting Stent Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) Trial. Methods and results Evaluation of the Xience Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization is a prospective, randomized multicenter trial designed to establish the efficacy and safety of percutaneous coronary intervention (PCI) with the everolimus-eluting stent compared with coronary artery bypass graft (CABG) surgery in subjects with unprotected left-main coronary artery (ULMCA) disease and low-intermediate anatomical SYNTAX scores (<33). After completion of patient recruitment in EXCEL, the SYNTAX Score II was prospectively applied to predict 4-year mortality in the CABG and PCI arms. The 95% prediction intervals (PIs) for mortality were computed using simulation with bootstrap resampling (10 000 times). For the entire study cohort, the 4-year predicted mortalities were 8.5 and 10.5% in the PCI and CABG arms, respectively [odds ratios (OR) 0.79; 95% PI 0.43–1.50). In subjects with low (≤22) anatomical SYNTAX scores, the predicted OR was 0.69 (95% PI 0.34–1.45); in intermediate anatomical SYNTAX scores (23–32), the predicted OR was 0.93 (95% PI 0.53–1.62). Based on 4-year mortality predictions in EXCEL, clinical characteristics shifted long-term mortality predictions either in favour of PCI (older age, male gender and COPD) or CABG (younger age, lower creatinine clearance, female gender, reduced left ventricular ejection fraction). Conclusion The SYNTAX Score II indicates at least an equipoise for long-term mortality between CABG and PCI in subjects with ULMCA disease up to an intermediate anatomical complexity. Both anatomical and clinical characteristics had a clear impact on long-term mortality predictions and decision making between CABG and PCI.
    European Heart Journal 01/2015; DOI:10.1093/eurheartj/ehu518
  • European Heart Journal 12/2014; DOI:10.1093/eurheartj/ehu473
  • European Heart Journal 12/2014; DOI:10.1093/eurheartj/ehu298
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cardiovascular diseases are the leading cause of death globally. Depression is associated with an increased morbidity and mortality rate among cardiovascular (CV) patients. Early detection of, and intervention for, depression among CV patients can reduce morbidity and mortality, and save health care costs. However, information on the presence of depression and mental health care needs among patients hospitalized with acute cardiovascular conditions in the Middle East is lacking. Purpose: This study’s goals are to evaluate the prevalence of depression or mood disturbances and to find ways to effectively manage depression. Methods: A cross-sectional survey was conducted with 1000 Arab patients hospitalized with acute cardiac conditions between January, 2013 and March, 2014 at a hospital in Qatar. Inclusion criteria were; ≥20 years of age, agreeing to participate in the study (98% response rate) and final confirmation of acute cardiac conditions (mainly acute coronary syndrome or heart failure). Face-to-face interviews were conducted using structured survey questionnaires which included an Arabic demographic questionnaire and the self report Arabic version of the Beck Depression Inventory 2nd Edition (BDI-II). Results: 84% of the patients rated their health as excellent or good, 16% rated as poor, 17% considered themselves depressed and 7% said that they had a confirmed history of depression. Of the patients with a history of depression, 31% were receiving medical therapy. Evaluation by the BDI-II indicated that 80% of the patients had no depressive symptoms, 15% suffered low levels of depression and 5% with significant levels of depression. Twice as many females than males were assessed having depression. While 68% and 36% of the patients agreed to share their mental health information with family and friends respectively, only 0.8% agreed to share it with a mental health clinician on a weekly basis. Conclusion: Depression and mood disturbance is common among Middle Eastern patients hospitalize with acute cardiac conditions, more so among women when compared to men. Understanding ways to evaluate depression among different ethnicities is important. To improve quality of life and survival of cardiovascular patients, increase awareness, early recognition of and culturally appropriate treatment for depression are necessary in Qatar.
    European Heart Journal 10/2014; European Heart Journal: Acute Cardiovascular Care 2014(3):74.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: Currently, an echocardiogram presents the left ventricle (LV) based on images obtained from ultrasound methods. Utilizing mathematical equations, specific echocardiographic data may provide more detailed, valuable and practical information for physicians. In our project using appropriate mathematically based softwares, we have attempted to create a novel software capable of demonstrate LV model in normal hearts. Methods: Echocardiography was performed on 50 healthy volunteers. Data evaluated included: velocity (radial, longitudinal, rotational and vector point), displacement (longitudinal and rotational), strain rate (longitudinal and circumferential) and strain (radial, longitudinal and circumferential) of all 16 LV myocardial segments. Using these data, force vectors of myocardial samples were estimated by MATLAB and LSDYNA softwares, interfaced in the echocardiograph system. Dynamic orientation contraction (through the cardiac cycle) of every individual myocardial fiber could be created by adding together the sequential steps of the multiple fragmented sectors of that fiber. This way we attempted to mechanically illustrate the global LV model. Results: LV Myocardial modeling: Our study shows that in normal cases myocardial fibers initiate from the posterior-basal region of the heart, continues through the LV free wall, reaches the septum, loops around the apex, ascends, and ends at the superior-anterior edge of LV. Conclusion: We were able to define the whole LV myocardial model mathematically, for the first time, by MATLAB software and LSDYNA software in normal subjects. This will enable physicians to diagnose and follow-up many cardiac diseases when this software is interfaced within echocardiographic machines.
    European Heart Journal 10/2014;
  • European Heart Journal 10/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: AIMS: The aim of the present study was to clarify the significance of myocardial ultrastructural changes in patients with dilated cardiomyopathy (DCM). METHODS AND RESULTS: Endomyocardial biopsy of the left ventricle was performed in 250 consecutive DCM patients (54.9 ± 13.9 years, 79% men), presenting initially as decompensated heart failure (HF). Myofilament changes of cardiomyocytes were evaluated by electron microscopy and compared with clinical and morphometric data. Mortality and HF recurrence were evaluated during the follow-up period. During the follow-up period (4.9 ± 3.9 years), 24 patients (10%) died and 67 (27%) were readmitted because of HF recurrence, including those who had died because of HF. Myofilament changes, classified as either focal derangement of myofilaments (sarcomere damage) or diffuse myofilament lysis (disappearance of most sarcomeres in cardiomyocytes), were identified in 164 patients (66%). Multivariate analysis identified a family history of DCM [hazard ratio (HR) 4.763; 95% confidence interval (CI) 1.012-12.518], atrial fibrillation (HR 6.132; 95% CI 2.188-17.180), haemoglobin level (HR 0.685; 95% CI 0.528-0.889), and diffuse myofilament lysis (HR 4.048; 95% CI 1.427-11.481) as independent predictors of mortality. A family history of DCM (HR 2.268; 95% CI 1.276-4.030), haemoglobin level (HR 0.876; 95% CI 0.785-0.979), focal derangement of myofilaments (HR 7.431; 95% CI 2.916-18.934), and diffuse myofilament lysis (HR 6.480; 95% CI 2.403-17.473) were predictors of readmission due to HF recurrence. CONCLUSIONS: In DCM patients with first-decompensated HF, myofilament changes are strongly associated with mortality and HF recurrence.
    European Heart Journal 10/2014; DOI:10.1093/eurheartj/ehu404
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: The aim of this study is to determine the factors that are associated with the use of ionotropic support during hospitalization in heart failure patients and the outcomes. Methods: We studied the medical records of 7,069 patients with decompensating heart failure who were hospitalized from 1990 to 2010. We performed multivariate analysis on the demographics and clinical characteristics of these patients. Results: 686 patients (9.7%) received intravenous ionotropic support after admission. Patients receiving ionotropes were more likely to be female (38.9% Vs 33.1%, p=0.002), marginally older (62 Vs 61.5 years, p=0.09), with chronic renal impairment (18.2% Vs 7.5%, p<0.001), dyslipidemic (22.7% Vs 18.2%, p=0.004), hypertensive (66.3% Vs 55.6%,p<0.001), obese (8.9% Vs 5.6%, p<0.001), hyperglycemic(10 Vs 9.2 mmol/l, p=0.02), hypercreatinemic (156 Vs 116µmol/L, p<0.001), on dialysis (1.6% Vs 0.2%, p<0.001),troponin positive (23.5% Vs 15.1%, p<0.001), had STEMI (32.1% Vs 25.0%, p<0.001), with aortic regurgitation (16.9% Vs 3.5%, p<0.001), cardiomyopathy (14.3% Vs 11.8%,p=0.06) and had PCI (2.5% Vs 1.3%, p=0.02). Interestingly, patients receiving ionotropes were less likely to have intraaortic balloon pump support (2.3% Vs 6.4%, p<0.001) and have better LV ejection fraction (LVEF>50%, 22.9% Vs 16.1%, p<0.001). There was no difference in the mean plasma BNP and CK-MB levels (p=0.21 and 0.73 respectively). Heart failure patients on ionotropes also suffered from significantcomplications including ventricular tachycardia (2.3% Vs 1.0%, p=0.002), prolonged hospital stay (7.0 Vs 5.6 days,p<0.001), cardiac arrest (22.0% Vs 5.1%, p<0.001) and in hospital mortality (25.8% Vs 6.1%, p<0.001). Conclusion: Conventional cardiac risk factors predict the use of ionotropic support in heart failure patients, even though female is more at risk. Plasma BNP and CK-MB do not seem to influence the likelihood of using ionotropes. Better LVEF observed in ionotropic group may be explained by the susceptibility of these patients to a sudden drop in ejection fraction, even though small, compared to patients pre-conditioned to chronic low ejection fraction. However,further study is required to investigate this observation.
    European Heart Journal 10/2014; 3(1):1–213.